OncoMatch/Clinical Trials/NCT06455124
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
Is NCT06455124 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including PD-1 antibody and Capecitabine for rectal cancer.
Treatment: PD-1 antibody · Capecitabine · Oxaliplatin — This is a single arm phase II study to explore the 3y LRFS and safety for high-risk early rectal cancer after local excision with short-course radiotherapy and chemo-immunotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MMR proficient
microsatellite repair status is MSS/pMMR
Excluded: DPYD deficiency
DPD deficiency
Disease stage
Required: Stage PT1, PT2
Grade: high gradepoorly differentiated
pT1 after local excision ... with at least one of the high-risk features including ... high grade or poorly differentiated ... or pT2 tumor
Demographics
Prior therapy
Cannot have received: anti-cancer therapy
without previous anti-cancer therapy or immunotherapy
Cannot have received: immunotherapy
without previous anti-cancer therapy or immunotherapy
Lab requirements
Blood counts
neutrophils≥1.5×10^9/l, hb≥90g/l, plt≥100×10^9/l
Kidney function
cr≤ 1 uln
Liver function
alt/ast ≤2.5 uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06455124 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MMR?
Yes, MMR proficient is a required biomarker for enrollment.
Are patients with DPYD alterations eligible?
No. DPYD deficiency is an exclusion criterion.
What disease stage is eligible?
Stage PT1 or PT2 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages